Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2023-10-23
Product name:
HEMGENIX
DIN:
02542560
Product Monograph/Veterinary Labelling:
Date:
2023-10-23
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
CSL BEHRING CANADA INC
1460
55 Metcalfe Street
Ottawa
Ontario
Canada
K1P 6L5
Class:
Human
Dosage form(s):
Suspension
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
26:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
B02BD16 ETRANACOGENE DEZAPARVOVEC
Active ingredient group (AIG) number:See footnote5
0165161002
| Active ingredient(s) | Strength |
|---|---|
| ETRANACOGENE DEZAPARVOVEC | 10000000000000 GENOME COPIES / ML |